Abstract:Mounting evidence indicates that the stimulator of interferon genes (STING) pathway is critical for the effectiveness of standard cancer treatments. However, systemic delivery of STING agonists remains a challenge due to poor tumor-targeting and unwanted toxicities. Here we describe a robust tumor-targeted STING agonist, ZnCDA, formed by the encapsulation of bacterial-derived cyclic dimeric adenosine monophosphate (CDA) in nanoscale coordination polymers. Intravenously injected ZnCDA prolonged CDA circulation and efficiently targeted tumors, mediating robust antitumor effects in a diverse set of preclinical cancer models. Moreover, endothelial STING activation promotes the accumulation of ZnCDA in the tumor tissues by amplifying the enhanced permeability and retention (EPR) effect. In this study, we discover that type I IFN is not required for the antitumor effects of STING agonism by ZnCDA, indicating that differentially formulated STING activators may suppress tumor growth in different ways. Using metal- or dye-labelled nanoparticles, we identified a group of tumor-associated macrophages (TAMs) as the cellular target of ZnCDA in the tumor immune microenvironment. RNA-seq analysis indicated the modulation of TAMs for antigen processing and presentation via STING activation. We further showed that TAMs with ZnCDA uptake promoted an antitumor T cell response. Lastly, we utilized two immunologically “cold” tumor models, a fragment Panc02-SIY pancreatic cancer model and an intracranial GL261 glioma model, both of which represent intractable fatal human cancers, to provide a proof-of-concept strategy for combining ZnCDA with immune checkpoint blockade or radiotherapy in aggressive, difficult-to-treat tumors. a grant from the Ludwig Foundation and an NIH grant (R01CA262508) to R.R.W., NIH grants (R01CA223184 and R01CA216436) to W.L. and NIH grants (R35CA232109 and R01AI141333) to J.P.Y.T. A.P. is the recipient of a Walter Benjamin scholarship provided by the German Research Foundation (Deutsche Forschungsgemeinschaft). J.B. was supported by a Clinical Therapeutics Training Grant (T32GM007019).

Photochemically controlled activation of STING by CAIX-targeting photocaged agonists to suppress tumor cell growth

Discovery of Novel Thieno[2,3-d]imidazole Derivatives As Agonists of Human STING for Antitumor Immunotherapy Using Systemic Administration.

Discovery of a Photoactivatable Dimerized STING Agonist Based on the Benzo[b]selenophene Scaffold

Structure−Activity Relationship Study of Benzothiophene Oxobutanoic Acid Analogues Leading to Novel Stimulator of Interferon Gene (STING) Agonists

Structural Insights into a Shared Mechanism of Human STING Activation by a Potent Agonist and an Autoimmune Disease-Associated Mutation.

Extracellular matrix-degrading STING nanoagonists for mild NIR-II photothermal-augmented chemodynamic-immunotherapy

A 2D Nanoradiosensitizer Enhances Radiotherapy and Delivers STING Agonists to Potentiate Cancer Immunotherapy

Bioorthogonal Guided Activation of Cgas‐STING by Aie Photosensitizer Nanoparticles for Targeted Tumor Therapy And Imaging

Tumor-responsive Covalent Organic Polymeric Nanoparticles Enhancing STING Activation for Cancer Immunotherapy

Simultaneous Activation of Pyroptosis and cGAS‐STING Pathway with Epigenetic/ Photodynamic Nanotheranostic for Enhanced Tumor Photoimmunotherapy

A Trinity STING-activating Nanoparticle Harnesses Cancer Cell STING Machinery for Enhanced Immunotherapy

Decomposable Nanoagonists Enable NIR-Elicited cGAS-STING Activation for Tandem-Amplified Photodynamic-Metalloimmunotherapy

Advanced nanomaterials targeting activation of STING for enhanced cancer immunotherapy

Engineering the Immune Adaptor Protein STING as a Biologic

Ionizable STING-Activating Nanoadjuvants Enhance Tumor Immunogenicity and Potentiate Immunotherapy Efficacy in Solid Tumors

Design and syntheses of a bimolecular STING agonist based on the covalent STING antagonist

A STING agonist-loaded bispecific nanobioconjugate modulates macrophage immune responses to enhance antitumor immunotherapy

A DNA‐Modularized STING Agonist with Macrophage‐Selectivity and Programmability for Enhanced Anti‐Tumor Immunotherapy

Zinc-c-di-AMP nanoparticles target and suppress tumors via endothelial STING activation and tumor associated macrophage reinvigoration

An Immunocompetent Hafnium Oxide-Based STING Nanoagonist for Cancer Radio-immunotherapy

Simultaneous Photoactivation of Cgas‐sting Pathway and Pyroptosis by Platinum(II) Triphenylamine Complexes for Cancer Immunotherapy